

Sleep Apnea Treatment Noted as Cardioprotective

BY KATE JOHNSON
Montreal Bureau

BOSTON — Obstructive sleep apnea is a risk factor for cardiac arrhythmias, and the diagnosis and treatment of this sleep disorder should be considered in terms of cardioprotective benefit, according to Dr. Maria Teresa La Rovere.

In a study that she presented in a poster at the annual meeting of the Heart Rhythm Society, Dr. La Rovere found a significant correlation between oxygen desaturation in obstructive sleep apnea syndrome (OSAS) and bradyarrhythmias, but not tachyarrhythmias.

"We found strong evidence that bradyarrhythmias are related to sleep apnea syndrome—while for tachyarrhythmias, the role of oxygen desaturation is more controversial," Dr. La Rovere said in an interview.

Other factors may contribute to tachyarrhythmias, such as β_2 -agonist treatment, which was found to be more common among patients who had tachyarrhythmias, she said.

The study included 300 subjects who were referred for sleep studies because of snoring. OSAS was diagnosed in 248 (83%) of them.

Although there was a trend toward more arrhythmias in the patients with OSAS than in those without OSAS (18% vs. 11%), the difference was not significant, reported Dr. Rovere, a cardiologist at the Fondazione Salvatore Maugeri clinic in Pavia, Italy.

Patients who had arrhythmias were older than the nonarrhythmic subjects (58 vs. 52 years) and had more profound oxygen desaturation (23% vs. 15% total sleep time spent with less than 90% oxygen saturation).

Although no significant relationship was found between tachyarrhythmias and hypoxemia, bradyarrhythmias were significantly correlated. Patients with bradyarrhythmias had significantly more hypoxemia, compared with nonarrhythmic patients, with an apnea-hypopnea index of 54 vs. 31 and an oxygen saturation nadir of 69% vs. 77%.

Dr. La Rovere said a recently published study that was performed in the general population and that used a stricter definition of OSAS produced similar evidence that people with sleep-disordered breathing have between two and four times the odds of having complex cardiac arrhythmias, compared with those without sleep apnea (*Am. J. Respir. Crit. Care Med.* 2006;173:910-6).

That study showed that sleep-disordered breathing was associated with four times the odds of atrial fibrillation, three times the odds of nonsustained ventricu-

lar tachycardia, and almost twice the odds of complex ventricular ectopy, after adjustment of the data for age, sex, body mass index, and prevalent coronary heart disease.

Another recently published study showed that OSAS was associated with almost double the risk of stroke or death, even after adjustment for age, sex, race, smoking status, alcohol consumption, body mass index, diabetes mellitus, hyperlipidemia, atrial fibrillation, and hyper-

tension (*N. Engl. J. Med.* 2005;353:2034-41).

Although treatment of OSAS with continuous positive airway pressure (CPAP) is well established for the relief of sleep disturbances and improvement in quality of life, Dr. La Rovere said that physicians should also recognize its value in preventing the development of cardiac arrhythmias.

"The mechanism of breathing disorders also affects cardiac functioning. So in the long term, these subjects may also de-

velop heart failure," she said. "I think there is an increasing awareness."

Dr. La Rovere added that although CPAP not only prevents sleep-related heart rhythm disturbances, but can also correct them, it is advisable to consider a pacemaker for patients whose CPAP compliance is questionable.

"I know the CPAP will correct my patient's arrhythmia, but I do not know if my patient will use the CPAP," Dr. La Rovere said. ■



AtHOME

thanks to ARICEPT®'s overall effectiveness

**ARICEPT helps patients
be more like themselves longer™**

- Helped keep patients in the community for more than 5 years^{1*†}
- Is proven effective in cognition, function, and behavior²⁻⁵
- Caregivers spend less time assisting patients with everyday activities⁶
- Established safety and tolerability

* Results from an observational follow-up of nursing home placement in mild to moderate AD patients (MMSE 10-26) previously enrolled in 1 of 3 randomized, double-blind, placebo-controlled trials with open-label extension phases.

† As with all studies of this type, results may be attributable to various factors. ARICEPT treatment was one such factor.

ARICEPT is indicated for mild to moderate dementia of the Alzheimer's type.

The most common adverse events in clinical trials with ARICEPT were nausea, diarrhea, insomnia, vomiting, muscle cramps, fatigue, and anorexia. In clinical trials, syncopal episodes have been reported (2% for ARICEPT versus 1% for placebo). Cholinesterase inhibitors have the potential to increase gastric acid secretion. Patients at risk for developing ulcers, including those receiving concurrent NSAIDs, should be monitored closely for gastrointestinal bleeding.

Clinical studies of ARICEPT have shown no increase, relative to placebo, in the incidence of either peptic ulcer disease or gastrointestinal bleeding.

Please see brief summary of prescribing information on adjacent page.

ARICEPT®
(donepezil HCl)

ONCE-A-DAY
ODT™
Orally Disintegrating
Tablets (5-MG and 10-MG)

ONCE-A-DAY
ARICEPT®
(donepezil HCl)
5-MG AND 10-MG TABLETS

References: 1. Geldmacher DS, Provenzano G, McRae T, Mastey V, Ieni JR. Donepezil is associated with delayed nursing home placement in patients with Alzheimer's disease. *J Am Geriatr Soc.* 2003;51:937-944. 2. Winblad B, Engedal K, Soiminen H, et al, and the Donepezil Nordic Study Group. A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. *Neurology.* 2001;57:489-495. 3. Mohs RC, Doody RS, Morris JC, et al, for the "312" Study Group. A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients. *Neurology.* 2001;57:481-488. 4. Rogers SL, Doody RS, Mohs RC, Friedhoff LT, and the Donepezil Study Group. Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. *Arch Intern Med.* 1998;158:1021-1031. 5. Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhoff LT, and the Donepezil Study Group. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. *Neurology.* 1998;50:136-145. 6. Feldman H, Gauthier S, Hecker J, et al, and The Donepezil MSAD Study Investigators Group. Efficacy of donepezil on maintenance of activities of daily living in patients with moderate to severe Alzheimer's disease and the effect on caregiver burden. *J Am Geriatr Soc.* 2003;51:737-744. AR273436A